NYXH Quote, Financials, Valuation and Earnings

Celyad Oncology SA has a net margin of -1195.73% compared to Nyxoah SA's net margin of --. Nyxoah SA's return on equity of -96.48% beat Celyad Oncology SA's return on equity of --.

Nyxoah SA has a consensus price target of $11.23, signalling upside risk potential of 129.58%. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Nyxoah SA has higher upside potential than Celyad Oncology SA, analysts believe Nyxoah SA is more attractive than Celyad Oncology SA.

Nyxoah SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Celyad Oncology SA has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.796%.

Nyxoah SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nyxoah SA pays -- of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend.

Nyxoah SA quarterly revenues are $2.3M, which are larger than Celyad Oncology SA quarterly revenues of --. Nyxoah SA's net income of -$27.6M is higher than Celyad Oncology SA's net income of --. Notably, Nyxoah SA's price-to-earnings ratio is -- while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nyxoah SA is 29.02x versus 37.01x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.

Galapagos NV has a net margin of -1195.73% compared to Nyxoah SA's net margin of -286.67%. Nyxoah SA's return on equity of -96.48% beat Galapagos NV's return on equity of -16.48%.

Nyxoah SA has a consensus price target of $11.23, signalling upside risk potential of 129.58%. On the other hand Galapagos NV has an analysts' consensus of $27.45 which suggests that it could fall by -13.07%. Given that Nyxoah SA has higher upside potential than Galapagos NV, analysts believe Nyxoah SA is more attractive than Galapagos NV.

Nyxoah SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Galapagos NV has a beta of 0.185, suggesting its less volatile than the S&P 500 by 81.495%.

Nyxoah SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galapagos NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nyxoah SA pays -- of its earnings as a dividend. Galapagos NV pays out -- of its earnings as a dividend.

Nyxoah SA quarterly revenues are $2.3M, which are smaller than Galapagos NV quarterly revenues of $83.2M. Nyxoah SA's net income of -$27.6M is higher than Galapagos NV's net income of -$238.4M. Notably, Nyxoah SA's price-to-earnings ratio is -- while Galapagos NV's PE ratio is 21.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nyxoah SA is 29.02x versus 6.57x for Galapagos NV. Usually stocks with elevated PS ratios are considered overvalued.

MDxHealth SA has a net margin of -1195.73% compared to Nyxoah SA's net margin of -29.2%. Nyxoah SA's return on equity of -96.48% beat MDxHealth SA's return on equity of -548.42%.

Nyxoah SA has a consensus price target of $11.23, signalling upside risk potential of 129.58%. On the other hand MDxHealth SA has an analysts' consensus of $7.0400 which suggests that it could grow by 95.56%. Given that Nyxoah SA has higher upside potential than MDxHealth SA, analysts believe Nyxoah SA is more attractive than MDxHealth SA.

Nyxoah SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -557,066.812, suggesting its less volatile than the S&P 500 by 55706781.163%.

Nyxoah SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nyxoah SA pays -- of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend.

Nyxoah SA quarterly revenues are $2.3M, which are smaller than MDxHealth SA quarterly revenues of $27.4M. Nyxoah SA's net income of -$27.6M is lower than MDxHealth SA's net income of -$8M. Notably, Nyxoah SA's price-to-earnings ratio is -- while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nyxoah SA is 29.02x versus 1.72x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

UCB SA has a net margin of -1195.73% compared to Nyxoah SA's net margin of --. Nyxoah SA's return on equity of -96.48% beat UCB SA's return on equity of 13.88%.

Nyxoah SA has a consensus price target of $11.23, signalling upside risk potential of 129.58%. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Nyxoah SA has higher upside potential than UCB SA, analysts believe Nyxoah SA is more attractive than UCB SA.

Nyxoah SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison UCB SA has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.475%.

Nyxoah SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.55% to investors and pays a quarterly dividend of $0.79 per share. Nyxoah SA pays -- of its earnings as a dividend. UCB SA pays out 15.96% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Nyxoah SA quarterly revenues are $2.3M, which are larger than UCB SA quarterly revenues of --. Nyxoah SA's net income of -$27.6M is higher than UCB SA's net income of --. Notably, Nyxoah SA's price-to-earnings ratio is -- while UCB SA's PE ratio is 38.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nyxoah SA is 29.02x versus 7.52x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.